Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04492514 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

COVID 19
SARS-CoV 2
Pneumonia

Interventions

DRUG: Mavrilimumab
DRUG: Placebo

Sponsor

Kristin Hudock

Collaborators

[object Object]